Decoding Inflammatory Bowel Disease (IBD) progression involves understanding how gut microbiota and host genetic changes correlate with disease severity. A recent study developed a multi-omics framework combining gut microbiota profiling (via fecal 16S rRNA sequencing) and host transcriptomics (RNA-seq) to accurately stage IBD.
Decoding Inflammatory Bowel Disease (IBD) progression involves understanding how gut microbiota and host genetic changes correlate with disease severity. A recent study developed a multi-omics framework combining gut microbiota profiling (via fecal 16S rRNA sequencing) and host transcriptomics (RNA-seq) to accurately stage IBD. This approach aimed to enable non-invasive disease monitoring and personalized therapeutic strategies.
The study analyzed 97 participants (74 IBD patients and 23 healthy controls) and found that IBD patients exhibited systemic inflammation and gut barrier dysfunction, reflected in abnormal clinical markers like CRP, ESR, and fecal calprotectin. Microbial diversity was significantly reduced in IBD patients, worsening with disease severity due to dysbiosis.
Key microbial biomarkers were identified for each disease stage, such as Bifidobacterium catenulatum in remission and Bacteroides uniformis in severe cases. Host transcriptomic analysis revealed stage-specific genes like YIPF4 and ALAS2, highlighting immune and metabolic changes. Functional pathway analysis showed dynamic immune responses, with remission linked to healing and severe IBD associated with inflammation and tissue damage.
Machine learning models achieved high predictive accuracy (AUC = 0.79–0.80) for staging IBD, leveraging microbial and genetic data. Cross-omics analysis demonstrated coordinated shifts between gut microbes and host gene expression, emphasizing their interplay in disease progression.
Despite limitations like small sample size and taxonomic resolution, the study's multi-omics approach offers a robust tool for understanding IBD and guiding precision treatments. Future research with larger cohorts and real-time biomarker tracking could transform IBD management, enabling personalized care and non-invasive monitoring.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.